Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

被引:1036
作者
Turk, DC [1 ]
Dworkin, RH
Allen, RR
Bellamy, N
Brandenburg, N
Carr, DB
Cleeland, C
Dionne, R
Farrar, JT
Galer, BS
Hewitt, DJ
Jadad, AR
Katz, NP
Kramer, LD
Manning, DC
McCormick, CG
McDermott, MP
McGrath, P
Quessy, S
Rappaport, BA
Robinson, JP
Royal, MA
Simon, L
Stauffer, JW
Stein, W
Tollett, J
Witter, J
机构
[1] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA
[2] Univ Rochester, Rochester, NY USA
[3] AstraZeneca, Wilmington, DE USA
[4] Univ Queensland, St Lucia, Qld 4067, Australia
[5] Pfizer Pharmaceut Grp, New York, NY USA
[6] Tufts Univ, Dept Anesthesiol, Medford, MA 02155 USA
[7] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA
[9] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[10] Endo Pharmaceut Inc, Chadds Ford, PA USA
[11] Ortho McNeil Pharmaceut Inc, Raritan, NJ USA
[12] Univ Toronto, Toronto, ON, Canada
[13] Univ Hlth Network, Toronto, ON, Canada
[14] Harvard Univ, Cambridge, MA 02138 USA
[15] Purdue Pharma, Stamford, CT USA
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] NIH, Bethesda, MD 20892 USA
[18] Dalhousie Univ, Dept Psychol, Halifax, NS, Canada
[19] GlaxoSmithKline, Res Triangle Pk, NC USA
[20] US FDA, Rockville, MD 20857 USA
[21] Univ Washington, Dept Phys Med & Rehabil, Seattle, WA 98195 USA
[22] Elan Pharmaceut, San Diego, CA USA
[23] Abbott Labs, Lake Forest, IL USA
[24] Univ Calif San Diego, La Jolla, CA 92093 USA
[25] US Dept Vet Affairs, Washington, DC USA
关键词
chronic pain; clinical trials; assessment; outcomes; quality of life; physical functioning; emotional functioning; adverse events; global ratings;
D O I
10.1016/j.pain.2003.08.001
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Objective. To provide recommendations for the core outcome domains that should be considered by investigators conducting clinical trials of the efficacy and effectiveness of treatments for chronic pain. Development of a core set of outcome domains would facilitate comparison and pooling of data, encourage more complete reporting of outcomes, simplify the preparation and review of research proposals and manuscripts, and allow clinicians to make informed decisions regarding the risks and benefits of treatment. Methods. Under the auspices of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), 27 specialists from academia. governmental agencies, and the pharmaceutical industry participated in a consensus meeting and identified core outcome domains that should be considered in clinical trials of treatments for chronic pain. Conclusions. There was a consensus that chronic pain clinical trials should assess outcomes representing six core domains: (1) pain, (2) physical functioning, (3) emotional functioning, (4) participant ratings of improvement and satisfaction with treatment, (5) symptoms and adverse events, (6) participant disposition (e.g. adherence to the treatment regimen and reasons for premature withdrawal from the trial). Although consideration should be given to the assessment of each of these domains, there may be exceptions to the general recommendation to include all of these domains in chronic pain trials. When this occurs, the rationale for not including domains should be provided. It is not the intention of these recommendations that assessment of the core domains should be considered a requirement for approval of product applications by regulatory agencies or that a treatment must demonstrate statistically significant effects for all of the relevant core domains to establish evidence of its efficacy. (C) 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:337 / 345
页数:9
相关论文
共 48 条
[1]
THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]
Physical symptoms distress index - A sensitive tool to evaluate the impact of pharmacological agents on quality of life [J].
Anderson, RB ;
Hollenberg, NK ;
Williams, GH .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (07) :693-700
[3]
Anderson RB., 1994, DRUG INF J, V28, P89, DOI 10.1177/009286159402800112
[4]
[Anonymous], 1991, ADV PAIN RES THER
[5]
[Anonymous], 1982, The challenge of pain
[6]
Explaining high rates of depression in chronic pain: A diathesis-stress framework [J].
Banks, SM ;
Kerns, RD .
PSYCHOLOGICAL BULLETIN, 1996, 119 (01) :95-110
[7]
Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[8]
Bellamy N, 1997, J RHEUMATOL, V24, P799
[9]
BENZON RA, 1994, QUAL LIFE RES, V6, P547
[10]
Brooks P., 2001, Rheumatology (Oxford), V40, P896, DOI 10.1093/rheumatology/40.8.896